InjectionClinical Overview
Ceftazidime and Avibactam is an advanced carbapenem-sparing antimicrobial agent. Ceftazidime is an anti-pseudomonal third-generation cephalosporin, and avibactam is a novel non-beta-lactam beta-lactamase inhibitor that inhibits class A (including KPC carbapenemases), class C (AmpC), and certain class D (OXA-48) beta-lactamases. Indicated for complicated intra-abdominal infections, complicated urinary tract infections, hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Administered solely in hospital/ICU settings by slow intravenous infusion over 2 hours after dilution in 0.9% Normal Saline or 5% Dextrose. Regimen must be managed by infectious disease specialists based on microbial sensitivity.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, diarrhea, headache, infusion site phlebitis, vomiting, dizziness. Rare/Severe: Neurological toxicity (encephalopathy, myoclonus, seizures in renal impairment), Clostridioides difficile colitis, and Coombs' test seroconversion.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Dosage adjustment is strictly mandatory in patients with renal clearance <= 50 mL/min. Monitor renal function and neurological status closely throughout treatment. Reserve strictly for proven or suspected MDR pathogens to preserve antimicrobial efficacy.
Schedule H1 (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Ceftazidime Injection 1g
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime Injection 250mg
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime Injection 500mg
Ceftazidime is a third-generation parenteral cephalosporin bactericidal antibiotic recognized for its high intrinsic activity against Pseudomonas aeruginosa. It acts by inhibiting bacterial cell wall synthesis. Indicated for severe hospital-acquired pneumonia, pseudomonal bacteremia, empirical therapy for febrile neutropenia, complicated urinary tract infections, cystic fibrosis pulmonary exacerbations, and intra-abdominal infections.
Ceftazidime 250mg + Tazobactum 31.25mg Injection
Ceftazidime and Tazobactam is a parenteral combination designed to combat resistant Pseudomonas aeruginosa and beta-lactamase-producing Enterobacteriaceae. Ceftazidime provides high intrinsic anti-pseudomonal bactericidal activity, while tazobactam inhibits beta-lactamases that would otherwise hydrolyze the cephalosporin ring. Indicated for nosocomial pneumonia, febrile neutropenia, complicated intra-abdominal infections, and severe urinary tract infections.